A primary clinical goal for TRPA1 modulation has been novel analgesics31, but developmental drugs based on TRPA1 antagonism that have reached phase II clinical trials have also been aimed at neuropathy and respiratory disorders32. The gene discussed is TRPA1; the disease is neuropathy.